Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Madison, Wisconsin

Phase 3 cancer trials in Madison, WI

46 Phase 3 cancer studies are recruiting participants at sites in Madison as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Madison at a glance

Breast cancer studies recruiting in Madison

Basic details from each study's public record (the 30 most recently updated of 46). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    SSM Health Dean Medical Group ( Site 0087)
    Registry record
    NCT06393374 · updated
  2. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Wisconsin-Madison ( Site 0024)
    Registry record
    NCT06966700 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT06058377 · updated
  4. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Relay Therapeutics, Inc.
    Study site
    University of Wisconsin Carbone Cancer Center- University Hospital
    Registry record
    NCT06982521 · updated
  5. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    • Phase 3
    • Ages 18 to 60
    • Female participants
    Sponsor
    NRG Oncology
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT05879926 · updated
  6. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Circuit Clinical/SSM Health Dean Medical Group ( Site 0039)
    Registry record
    NCT07060807 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Madison, WI on ClinicalTrials.gov.

Lung cancer studies recruiting in Madison

  1. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital · William S Middleton VA Medical Center
    Registry record
    NCT04267848 · updated
  2. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Circuit Clinical/SSM Health Dean Medical Group ( Site 0129)
    Registry record
    NCT06345729 · updated
  3. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical
    Registry record
    NCT06119581 · updated
  4. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    University Hospital and UW Health Clinics
    Registry record
    NCT06890598 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Madison, WI on ClinicalTrials.gov.

Prostate cancer studies recruiting in Madison

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital · William S Middleton VA Medical Center
    Registry record
    NCT04423211 · updated
  2. Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    William S Middleton VA Medical Center
    Registry record
    NCT06931340 · updated
  3. Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT07200830 · updated
  4. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University Hospital and UW Health Clinics ( Site 0065)
    Registry record
    NCT06925737 · updated
  5. Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    NRG Oncology
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT05946213 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Madison, WI on ClinicalTrials.gov.

Melanoma studies recruiting in Madison

  1. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    University of Wisconsin Carbone Cancer Center
    Registry record
    NCT06246916 · updated
  2. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    University of Wisconsin
    Registry record
    NCT06743126 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Madison, WI on ClinicalTrials.gov.

Lymphoma studies recruiting in Madison

  1. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Nuvation Bio Inc.
    Study site
    University of Wisconsin Health
    Registry record
    NCT05303519 · updated
  2. A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical ( Site 0048) · University Hospital and UW Health Clinics ( Site 0006)
    Registry record
    NCT06136559 · updated
  3. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT06724237 · updated
  4. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    SSM Health Dean Medical Group ( Site 0140)
    Registry record
    NCT06717347 · updated
  5. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT04269902 · updated
  6. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT05675410 · updated
  7. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT03150693 · updated
  8. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT05976763 · updated
  9. Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    University of Wisconsin Carbone Cancer Center - Eastpark Medical Center · University of Wisconsin Carbone Cancer Center - University Hospital
    Registry record
    NCT07215910 · updated
  10. Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

    • Phase 3
    • Ages 65 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    William S Middleton VA Medical Center
    Registry record
    NCT07321652 · updated
  11. A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    University of Wisconsin
    Registry record
    NCT06742996 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Madison, WI on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Madison

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US044
    Registry record
    NCT07522073 · updated
  2. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immuneering Corporation
    Study site
    University of Wisconsin Carbone Cancer Center
    Registry record
    NCT07562152 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Madison, WI on ClinicalTrials.gov.

Ask about studies near Madison

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Wisconsin

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call